Hong Kong Strengthens Biopharma Ecosystem to Support Global Clinical Research

Hong Kong is strengthening its position in the global biopharmaceutical sector by attracting companies focused on advanced therapeutic products (ATP) and supporting them with research infrastructure, regulatory alignment, and talent policies. Through efforts led by Invest Hong Kong (InvestHK), the city aims to provide firms from the Chinese Mainland and overseas with a base for research, clinical trials and international expansion. According to the Hong Kong government, these initiatives are designed to connect scientific capability with global regulatory pathways.

Biopharma firms expand research presence in Hong Kong

InvestHK has identified biopharmaceutical companies specialising in advanced therapeutic products as a priority sector. These therapies, which include cell and gene-based treatments, depend heavily on highly skilled researchers and sustained investment in research and development.

Frank Su, founder of a Chinese Mainland-based biopharma technology company established in 2016, recently expanded his company’s footprint by opening a new research and development centre at Hong Kong Science Park. The firm already operates R&D facilities in both the Chinese Mainland and the United States and focuses on developing cell therapy technologies.

Mr Su said the decision to establish a base in Hong Kong was influenced by the city’s intellectual property protections and the research capabilities of its universities and medical schools. He also pointed to government-backed programmes and talent policies that support companies working in emerging biomedical fields.

Policy programmes support research and investment

Industry leaders note that access to talent and capital is central to the growth of the biotechnology sector. Hong Kong has introduced programmes designed to strengthen this ecosystem, including the Clinical Translational Catalyst initiative at the Science Park and the Research Talent Hub.

These initiatives are intended to support early-stage research translation, reduce investment risk, and help companies scale their development pipelines. They also complement broader government efforts to strengthen the city’s innovation ecosystem, including initiatives highlighted in Hong Kong’s strategy to link talent and technology for regional growth.

Global regulatory recognition strengthens market access

Another factor attracting companies is Hong Kong’s alignment with international pharmaceutical regulatory standards. The city amended its Pharmacy & Poisons Ordinance in 2020 to ensure that clinical trials and manufacturing processes for advanced therapeutic products follow globally recognised standards under the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Hong Kong joined the scheme earlier, in 2016, when the Pharmacy & Poisons Board became a participating authority. As a result, clinical trial data generated in Hong Kong can be recognised by other PIC/S members, including the United Kingdom, Canada, Australia and the European Union.

This regulatory alignment provides companies with a pathway to international markets. For many firms from the Chinese Mainland, conducting trials in Hong Kong allows them to pursue product development while ensuring global acceptance of their research results.

Industry dialogue on advanced therapeutic products

To support industry engagement, InvestHK will host a forum on advanced therapeutic products on 17 April. The event will bring together government officials and industry specialists to discuss regulatory developments, the role of PIC/S, and recent progress in ATP research.

Participants will also examine how companies can use Hong Kong’s regulatory framework and research environment to scale their operations globally. The forum reflects broader government initiatives to expand innovation-driven industries and build a competitive life sciences ecosystem, alongside policies designed to simplify global tech talent access for growth.